MX2013013153A - La expresion de kiaa1456 predice la supervivencia en pacientes con cancer de colon. - Google Patents

La expresion de kiaa1456 predice la supervivencia en pacientes con cancer de colon.

Info

Publication number
MX2013013153A
MX2013013153A MX2013013153A MX2013013153A MX2013013153A MX 2013013153 A MX2013013153 A MX 2013013153A MX 2013013153 A MX2013013153 A MX 2013013153A MX 2013013153 A MX2013013153 A MX 2013013153A MX 2013013153 A MX2013013153 A MX 2013013153A
Authority
MX
Mexico
Prior art keywords
kiaa1456
patients
colon cancer
expression predicts
predicts survival
Prior art date
Application number
MX2013013153A
Other languages
English (en)
Inventor
Juan Carlos Lacal Sanjuán
Fátima Valdés Mora
Original Assignee
Traslational Cancer Drugs Pharma S L
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Traslational Cancer Drugs Pharma S L filed Critical Traslational Cancer Drugs Pharma S L
Publication of MX2013013153A publication Critical patent/MX2013013153A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57407—Specifically defined cancers
    • G01N33/57419—Specifically defined cancers of colon
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/118—Prognosis of disease development
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Analytical Chemistry (AREA)
  • Pathology (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Molecular Biology (AREA)
  • Physics & Mathematics (AREA)
  • General Health & Medical Sciences (AREA)
  • Oncology (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Biophysics (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Cell Biology (AREA)
  • Food Science & Technology (AREA)
  • Medicinal Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Investigating Or Analysing Biological Materials (AREA)

Abstract

La invención se refiere a métodos para decidir sobre la terapia en un sujeto que padece cáncer colorrectal así como para predecir el desenlace clínico de un paciente que padece cáncer colorrectal basado en el nivel de expresión de KIAA1456 que comprende determinar el nivel de expresión del gen KIAA1456. La invención se refiere asimismo a kits y usos de los mismos que comprenden reactivos adecuados para la determinación del nivel de expresión del gen KIAA1456.
MX2013013153A 2011-05-12 2012-05-11 La expresion de kiaa1456 predice la supervivencia en pacientes con cancer de colon. MX2013013153A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP11382144 2011-05-12
US201161490658P 2011-05-27 2011-05-27
PCT/EP2012/058778 WO2012152922A1 (en) 2011-05-12 2012-05-11 Kiaa1456 expression predicts survival in patients with colon cancer

Publications (1)

Publication Number Publication Date
MX2013013153A true MX2013013153A (es) 2014-05-27

Family

ID=47138811

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2013013153A MX2013013153A (es) 2011-05-12 2012-05-11 La expresion de kiaa1456 predice la supervivencia en pacientes con cancer de colon.

Country Status (11)

Country Link
US (1) US20140329701A1 (es)
EP (1) EP2707499A1 (es)
JP (1) JP2014513975A (es)
KR (1) KR20140044329A (es)
CN (1) CN103649334A (es)
AU (1) AU2012252373A1 (es)
BR (1) BR112013028985A2 (es)
CA (1) CA2835721A1 (es)
MX (1) MX2013013153A (es)
RU (1) RU2013155198A (es)
WO (1) WO2012152922A1 (es)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR096507A1 (es) * 2013-05-30 2016-01-13 Fundació Institució Catalana De Recerca I Estudis Avançats Métodos y kits para el pronóstico del cáncer colorrectal
CN110873799A (zh) * 2019-12-09 2020-03-10 四川大学华西医院 Psmb4自身抗体检测试剂在制备肺癌筛查试剂盒中的用途

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE69933369D1 (en) 1998-04-03 2006-11-09 Compound Therapeutics Inc Adressierbare protein arrays
GB9928787D0 (en) 1999-12-03 2000-02-02 Medical Res Council Direct screening method
AU2002258518A1 (en) * 2001-03-14 2002-09-24 Millennium Pharmaceuticals, Inc. Nucleic acid molecules and proteins for the identification, assessment, prevention, and therapy of ovarian cancer
US20090215046A1 (en) * 2004-01-27 2009-08-27 Compugen Ltd. Novel nucleotide and amino acid sequences, and assays methods of use thereof for diagnosis of colon cancer
EP1782315A4 (en) * 2004-07-30 2009-06-24 Rosetta Inpharmatics Llc FORECAST FOR BREAST CANCER PATIENTS
EP2324123B1 (en) 2008-09-10 2016-07-20 Rutgers, The State University of New Jersey IMAGING INDIVIDUAL mRNA MOLECULES USING MULTIPLE SINGLY LABELED PROBES

Also Published As

Publication number Publication date
EP2707499A1 (en) 2014-03-19
US20140329701A1 (en) 2014-11-06
KR20140044329A (ko) 2014-04-14
AU2012252373A1 (en) 2013-12-05
BR112013028985A2 (pt) 2020-11-10
JP2014513975A (ja) 2014-06-19
WO2012152922A1 (en) 2012-11-15
RU2013155198A (ru) 2015-06-20
CN103649334A (zh) 2014-03-19
CA2835721A1 (en) 2012-11-15

Similar Documents

Publication Publication Date Title
MX2014006404A (es) Metodos y kits para el pronostico del cancer colorrectal.
MX2013012167A (es) Estratificaciones a base de bcma y terapia para pacientes con mieloma multiple.
EA201391074A1 (ru) Профили экспрессии генов рака толстой кишки и способы применения
PH12016501728A1 (en) Anti-angiogenesis therapy for the treatment of ovarian cancer
WO2012093821A3 (ko) 초기유방암의 예후 예측용 유전자 및 이를 이용한 초기유방암의 예후예측 방법
WO2013153458A3 (en) Method for the prognosis and treatment of cancer metastasis
MX341734B (es) Biomarcadores para la prediccion de la eficacia de una inmunoterapia contra el cancer.
TR201907389T4 (tr) Meme kanserinden kaynaklanan metastazlı kemik kanserinin prognozu ve tedavisine yönelik yöntem.
MX358541B (es) Metodos para predecir el riesgo de desarrollar hipertension.
MX2020001156A (es) Metodo para el pronostico y tratamiento de metastasis de cancer.
MX2013002084A (es) Biomarcadores y metodos de tratamiento.
NZ607282A (en) Method for using gene expression to determine prognosis of prostate cancer
WO2010124264A3 (en) Genetic variants in angiogenesis pathway associated with clinical outcome
WO2011153545A3 (en) Gene expression signature as a predictor of chemotherapeutic response in breast cancer
MX2012008730A (es) Metodos y composiciones para prediccion de riesgo, diagnosis, prognosis y tratamiento de desordenes pulmonares.
NZ701652A (en) Breast cancer prognosis, prediction of progesterone receptor subtype and|prediction of response to antiprogestin treatment based on gene expression
MX343801B (es) Biomarcadores de plasma de sangre para terapias de combinacion con bevacizumab para tratamiento de cancer de mama.
WO2014184679A3 (en) Method for the prognosis and treatment of renal cell carcinoma metastasis
MX2013011431A (es) Metodos para predecir y mejorar la supervivencia de pacientes con cancer gastrico.
MX339427B (es) Biomarcadores de plasma de sangre para terapias de combinacion con bevacizumab para tratamiento de cancer pancreatico.
WO2014078468A3 (en) Biomarkers for predicting clinical response of cancer patients to treatment with immunotherapeutic agent
EP2589665A4 (en) METHOD FOR PREDICTING THE THERAPEUTIC EFFECT OF IMMUNOTHERAPY ON CANCER PATIENT, AND SET OF GENES AND KIT FOR USE IN THE METHOD
SG179129A1 (en) Method for identifying whether a patient will be responder or not to immunotherapy
PH12015500388A1 (en) Cancer diagnostic and therapeutic method targeting molecules expressed in cancer stem cells
MX2013013153A (es) La expresion de kiaa1456 predice la supervivencia en pacientes con cancer de colon.

Legal Events

Date Code Title Description
FA Abandonment or withdrawal